When was Achilles Therapeutics founded?

Achilles Therapeutics was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Achilles Therapeutics located?

Achilles Therapeutics is headquartered in London, United Kingdom. It is registered at Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, England, SG1 2FX.

Who is the current CEO of Achilles Therapeutics?

Iraj Ali of Achilles Therapeutics.

Which legal entities is Achilles Therapeutics associated with?

Achilles Therapeutics is associated with Achilles Therapeutics Limited and 1 other.

How many employees does Achilles Therapeutics have?

As of Mar 01, 2026, the latest employee count at Achilles Therapeutics is 200 - 499.

Is Achilles Therapeutics a funded company?

Achilles Therapeutics is a funded company, having raised a total of $242M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 24, 2016.

When was the latest funding round of Achilles Therapeutics?

Achilles Therapeutics' latest funding was a $***** Grant (prize money) round on Jul 21, 2022, with participation from 1 investor.

Where does Achilles Therapeutics rank among its competitors?

Achilles Therapeutics ranks 32nd amongst 3341 active competitors, of which 1143 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Achilles Therapeutics?

Achilles Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Achilles Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Achilles Therapeutics is a public company based in London (United Kingdom), founded in 2016 by Karl Peggs, Charles Swanton, Sergio Quezada, Mark Lowdell and Mark Lowdell. It operates as a Developer of T-cell therapies for cancer. Achilles Therapeutics has raised $242M in funding from investors like Orbimed, RA Capital Management and Syncona. The company has 3341 active competitors, including 1143 funded and 799 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of T-cell therapies for cancer. Its therapeutics will target tumor neo-antigens, unique flags to the immune system present on the surface of every cancer cell. They develop therapeutics for lung cancer, recurrent metastatic melanoma, and head and neck squamous cell carcinomas.

Website: achillestx.com
Social
Email ID: *****@achillestx.com
Registered Address: Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, England, SG1 2FX

Key Metrics

Founded Year

2016

Location

London, United Kingdom

Stage

Public

Total Funding

$242M in 5 rounds

Latest Funding Round

Grant (prize money), Jul 21, 2022, $*****

Investors

Orbimed & 42 more

Ranked

32^nd among 3341 active competitors

Employee Count

200 - 499 as on Mar 01, 2026

Similar Companies

Senti Bio & 378 more

Exit Details

Public

View Achilles Therapeutics' full profile

Achilles Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Achilles Therapeutics Limited CIN: 10167668 , United Kingdom, Active	May 05, 2016	£0 - £1M (As on Sep 30, 2018)	118 (As on Dec 31, 2020)
ACHILLES THERAPEUTICS PLC CIN: 13027460 , United Kingdom, Active	Nov 17, 2020	-	-

Achilles Therapeutics got listed on Mar 31, 2021.

Click here to take a look at Achilles Therapeutics's IPO in detail

Achilles Therapeutics has raised a total funding of $242M over 5 rounds. Its first funding round was on May 24, 2016. Its latest funding round was a Grant (prize money) round on Jul 21, 2022 for $*****. 1 investor participated in its latest round. Achilles Therapeutics has 15 institutional investors and 28 angel investors.

Here is the list of recent funding rounds of Achilles Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 21, 2022	8975596	Grant (prize money)	4572312	2017883	7370172	7732206
Jun 01, 2021	1989581	Grant (prize money)	8447411	8518283	7155204	Europa
Nov 17, 2020	6871896	Series C	5259262	9842723	Orbimed & 1 more	RA Capital Management & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Achilles Therapeutics's funding rounds and investors

The founders of Achilles Therapeutics are Karl Peggs, Charles Swanton, Sergio Quezada, Mark Lowdell and Mark Lowdell.

Here are the details of Achilles Therapeutics' key team members:

Karl Peggs: Co-Founder of Achilles Therapeutics. They serve on the board of 1 company.
Charles Swanton: Co-Founder of Achilles Therapeutics.
Sergio Quezada: Co-Founder of Achilles Therapeutics.
Mark Lowdell: Co-Founder of Achilles Therapeutics.
Mark Lowdell: Co-Founder of Achilles Therapeutics.

Achilles Therapeutics' Board of Directors

Achilles Therapeutics's board has 8 active members. Michael Giordano, Karl Peggs, Iraj Ali, Derek Dirocco and Edwin Moses are part of team and Martin Murphy, Rogier Rooswinkel and Carsten Boess are independent board members.

Here is the list of Achilles Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
Karl Peggs	Team	-	Current	10y 1m
qfrqktl	Team	-	Current	3y 7m
xhdsxwr	Team	-	Current	4y 3m
winhj{p	Team	-	Current	5y 2m
ltfkpdn	Team	-	Current	5y 7m
dwijazf	Team	-	Past	4y 3m
Martin Murphy	Independent board member	-	Current	8y 5m
xevbyml	Independent board member	-	Current	5y 1m
oqeikps	Independent board member	-	Current	2y 4m
igedisf	Independent board member	-	Past	5y 2m
ho{k{zz	Independent board member	-	Past	5y 1m
jhebsnc	Independent board member	-	Past	6y 4m

View details of Achilles Therapeutics's Founder profiles and Board Members

Achilles Therapeutics' employee count trend

Achilles Therapeutics has 200 - 499 employees as of Mar 26. Here is Achilles Therapeutics's employee count trend over the years:

Employee count trend for Achilles Therapeutics

Uncover Achilles Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Achilles Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Achilles Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
32nd	Achilles Therapeutics 2016, London (United Kingdom), Public	Developer of T-cell therapies for cancer	$242M	HTIF, Boxer Capital & 41 others	68/100